CRIS
PRLY
A rapid, sensitive and easy-to-use point-of-care diagnostic kit for detection of high-risk HPV infection using CRISPR/Cas12 technology.
OVERVIEW
Cervical Cancer is the fourth-most common cause of death in women.
Nearly one-third of the cases coming from India.
1 in 50
Indian women develop cervical cancer in their lifetime
36.5%
of Indian female population is at risk of HPV infection
RISK OF CERVICAL CANCER
In India, 483.5 million women are at the risk of developing cervical cancer. Being the second most common cancer among Indian women.
15.2% of total cervical cancer deaths in the world occur in India.
More than 95% of Cervical Cancer cases are caused by the Human Papillomavirus or HPV, a mostly sexually transmitted virus.
Present scenario of cervical cancer screening
In India, there’s a lack of awareness about Cervical Cancer and HPV, sexual health taboos, especially among rural women and lack of low-cost, non-invasive screening tests.
Early screening and diagnosis brings down the mortality rate of cervical cancer by 50%.
Fewer than 1 in 10 women have been screened for cervical cancer in the last 5 years
OUR SOLUTION
Our project is a fast and sensitive diagnostic kit to detect the most oncogenic strain of HPV i.e. HPV16. Our kit would be cost-effective and easy to use.
It is designed for use in low-resource settings without the need for special equipment or trained professionals.
The kit is based on the detection of HPV16 DNA by using CRISPR/Cas12 technology. We chose CRISPR/Cas12a as it is a highly specific and sensitive reaction that can be easily carried out at room temperature. The kit also has a very low false-positive and false-negative testing rate.
WORKING ANIMATION
GO TO
MODEL
RESULTS
WEBAPP
HUMAN PRACTICES
HARDWARE
